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INTRODUCTION
Although anticancer agents are sometimes used to prolong
survival in advanced cancer patients with non-curative locally
advanced or metastatic lesions, many symptoms induced by the
cancer itself or the adverse events of anticancer agents burden
patients regardless of the type of cancer. Recent studies revealed
that hypogonadism with low serum testosterone levels is associ-
ated with advanced cancer and induces many cancer-related symp-
toms including depression, weight loss, albumin loss, sarcopenia,
topical inflammation, deterioration of pain, increase of opioid dose,
and cachexia (1-5). Currently, each symptom is individually treated
witha specific therapy. However, it is theoretically possible to treat
hypogonadism by androgen replacement therapy to solve all
problems at once. In the ARTFORM study, we prospectively
examine the efficacy of androgen replacement therapy for cancer-
related symptoms in male advanced cancer patients.
PATIENTS AND METHODS
Aim
We aim to evaluate the efficacy of testosterone enanthate in male
advanced cancer patients with non-curative locally advanced or
metastatic lesions.
Study design
Our ARTFORM study is an investigator- initiated, randomised
controlled trial involving a comparison of intramuscle injection of
testosterone enanthate with non-administration in male advanced
cancer patients with low possibility of complete recovery. Patients
are randomly assigned to testosterone enanthate administration
group or non-administration group, as shown in Figure 1.
Primary endpoint and additional measures
A validated health-related quality of life questionnaire, FAACT
ver4, and the Edmonton Symptom Assessment System (ESAS),
translated into Japanese, are administered before the treatment
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Figure 1. Trial overview
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and at 4, 8, and 12 weeks after treatment commences to compre-
hensively evaluate the various aspects of physical and psychoso-
cial well -being.
Eligibility criteria
Inclusion criteria require patients to be male ; have pathologi-
cally or cytologically confirmed cancer ; have non-curative locally
advanced or metastatic lesions ; know their diagnosis ; provide
written informed consent ; and have appropriate hepatic and renal
functionality as demonstrated in laboratory tests within 4 weeks
prior to registration : aspartate transaminase3.0upper limit of
normal (ULN), alanine transaminase3.0ULN, blood urea
nitrogen30 mg/dL, and serum creatinine3.0 mg/dL.
Patients are excluded if they are younger than 20 years old ;
have prostate cancer, past history of the disease, or severe benign
prostate hyperplasia defined as prostate volume40 mL with a
history of acute urinary retention ; have possible prostate cancer
with serum prostate specific antigen level4.0 ng/mL ; or are
considered by a principal or clinical investigator to be inappropriate
for participation in the present study for any other reason.
Informed consent : Ethics approval
The ARTFORMstudy is conducted in accordance with the Dec-
laration of Helsinki 1975, as revised in 2008. All treatments and ex-
aminations for hypogonadismare undertaken followingwritten in-
formed consent prior to registration. The ARTFORM study re-
ceived approval from the Institutional Review Board of Kanazawa
University.
Methods of recruitment and randomisation
Recruitment began in June 2013 and completion is planned by
December 2017. Eligible patients have their serum total and free
testosterone levels checked and if the total and free testosterone
level is2.31 ng/mL and 11.8 pg/mL, respectively, patients are
assigned to groupA and do not proceed to randomisation. If either
total or free testosterone level is2.31 ng/mL or11.8 pg/mL,
respectively, patients are randomly assigned to one of two groups :
non-administration (group B) or testosterone enanthate admini-
stration(groupC).
Administration of testosterone enanthate
Testosterone enanthate is injected in muscle of patients who are
assigned to the testosterone enanthate group at a dose of 250 mg
every 4 weeks. The administration of testosterone enanthate is
terminated when any of the following events occur : 1) the patient
withdraws written informed consent or opts out of the study ; 2) the
patient is no longer eligible for the study ; 3) cancer is completely
cured ; 4) the patient’s condition deteriorates and testosterone
enanthate is not appropriate ; 5) severe adverse events occur ; 6)
the patient’s compliance is poor ; or 7) the patient’s participation is
considered inappropriate bya principal or clinical investigator for
any other reason.
Data collection
All patients providing written informed consent to participate in
the ARTFORM study are asked to provide a complete medical
history. Clinical data obtained in the ARTFORM study include the
Eastern Cooperative Oncology Group PS, physical measurements
(age, height, body weight, body temperature, and blood pressure),
haematological measurements (e.g. white blood cell, red blood
cell, haemoglobin, haematocrit, and plateletcounts), general blood
biochemical measurements (e.g. total and free testosterone, alka-
line phosphatase, bone alkaline phosphatase, total bilirubin, cre-
atinine, liver enzymes, and electrolytes), cachexia-related biomark-
ers (IL-6, TNF alpha, IGF-1), urine analysis, and quality of life
questionnaires (FAACT ver4 and ESAS). Examinations are per-
formed every 4 weeks for 12 weeks (Figure 2). However, if a
principal or clinical investigator considers these examinations to
be necessary, they can be performed at any time.
Definition of endpoints
The primary endpoint is the difference in health-related quality of
life questionnaires between groups B and C at week 12.
Secondary endpoints are set in the ARTFORM study as fol-
lows :
1. Difference in health-related quality of life questionnaires, PS,
body weight, body mass index, dose of analgesic, and blood
data at registration between normal testosterone group (A)
and low testosterone groups(BandC).
2. Difference in PS, body weight, body mass index, dose of analge-
sic, blood data, cancer-specific survival, and overall survival
between groups B and C.
RESULTS
Patient enrolment and anticipated completion of enrolment
Our current expectation is that the final patient will be enrolled
by October 2017 and the entire study will be completed by De-
cember 2017. Recruitment began in June 2013 and cumulative
enrolment reached 70 cases as of February 2017.
DISCUSSION
Recent developments in cancer treatment have prolonged sur-
vival of advanced cancer patients, indicating that patients spend a
long time not only with cancer but also cancer-related symptoms.
Although prolonging life is the main goal of cancer treatment,
health-related quality of life should also be considered during the
period of anticancer treatment and best supportive care. Among
male advanced cancer patients with cachexia, up to 70% of patients
reportedly have hypogonadism defined as low serum testosterone
levels which could induce many cancer-related symptoms includ-
ing cachexia itself (1, 2, 6). Testosterone functions to keep males
healthy and decreases gradually with age (7, 8). Testosterone in-
creases bone mineral density and muscle mass (9, 10), improves
mental function and cognitive impairment (11, 12), decrease lower
urinary tract symptoms and nocturia (13, 14), and maintains cardio-
vascular health (15). On the other hand, androgen receptors in
Figure 2. A follow-up schedule
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prostate cancer cells are important drivers of cancer progression
and testosterone may be associated with carcinogenesis of prostate
cancer and deteriorate benign prostate hyperplasia(16-18).
Although androgen replacement therapy reportedly improves
symptoms caused by hypogonadism in non-cancer male patients,
there are few studies showing the efficacy of androgen replace-
ment therapy on symptoms in male advanced cancer patients (19).
There have been no prospective studies comparing continuous tes-
tosterone administration to non-administration conducted to date.
The ARTFORM study is the first study of its kind, and the efficacy of
androgen replacement therapy is prospectively assessed from a
patient perspective of direct clinical benefit using health-related
quality of life questionnaires comparing testosterone administra-
tion patients to non-administration patients. The study will clarify
the role of testosterone in male advanced cancer patients and the
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